BIOE — Bio Essence Corp
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1723059 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 500,537 | 319,353 | 215,795 | 205,373 | 789,032 | 36,177 | 2,216,552 |
| Dec 2025 | 1,479,454 | 1,143,421 | 1,029,627 | 1,029,087 | 422,474 | 0 | 2,495,367 |
| Sep 2025 | 136,800 | 95,760 | 14,253 | 12,998 | 184,534 | 28,741 | 3,286,514 |
| Jun 2025 | 259,123 | 168,644 | 61,223 | 59,864 | 112,692 | 0 | 3,227,670 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,183,852
Investing CF
$-114
Financing CF
$-1,147,675
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.01
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-9,347,700
Inventory
—
Receivables
$505,317
ST Investments
—
EBIT TTM
$1,320,146
Pretax Income TTM
$1,317,961
Interest Exp TTM
$2,185
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,375,914
EBITDA
$1,321,133
Free Cash Flow
$290,357
Enterprise Value
$13,349,054
Total Cash
$36,177
Total Debt
$1,565,959
Shares Out
46,809,000
Trailing EPS
$0.03
Book Value
$-0.03
ROE
—
ROA
143.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,897,566 | 900,011 | 896,197 | 422,474 | 2,495,367 | — | 1,569,753 |
| Dec 2024 | 323,940 | -459,438 | -1,308,796 | 281,024 | 3,250,114 | — | 623,865 |
| Dec 2023 | 0 | -345,590 | -971,879 | 2,758,580 | 4,418,874 | — | -1,025,673 |
| Dec 2022 | 621,590 | -511,138 | -809,679 | 1,547,725 | 4,786,140 | — | -703,241 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.01T | $1133.00 | — |
| JNJ | JOHNSON & JOHNSON | $579.83B | $240.87 | — |
| ABBV | AbbVie Inc. | $402.35B | $227.73 | — |
| MRK | Merck & Co., Inc. | $294.03B | $119.05 | — |
| NVS | NOVARTIS AG | $292.07B | $153.07 | — |
News headlines (Yahoo Finance, 1h cache)
Bio Essence Corporation (OTCQB: BIOE) to Acquire MediFlow AI Platform, Strengthening Its Human Health and Wellness Portfolio
2026-04-27 12:00 · Yahoo
BIO ESSENCE CORP (OTCQB:BIOE) Announces Approval for Upgrade to the OTCQB Market, Effective February 26, 2026
2026-03-03 13:00 · Yahoo
BIO ESSENCE CORP (OTC Pink: BIOE) Announces Commencement of Regulation A Tier 2 Offering for up to $5.0 Million
2026-02-03 14:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.